Moonshots EP 142: She Left Google to Build Tech That Could Save Millions w/ Mary Lou Jepsen

Summary

Deep-dive interview with Dr. Mary Lou Jepsen, CEO of Open Water, covering her career arc from MIT holographic video (1987) through Intel CTO, One Laptop per Child (with Nicholas Negroponte), Google X, Facebook/Oculus, and into her current mission: democratizing medical imaging and therapeutics. Jepsen is a brain tumor survivor, which directly motivated her pivot from consumer electronics to medical technology.

Open Water’s core technology exploits the fact that modern smartphone camera chips have pixels at the wavelength of light, enabling phase detection (holographic recording) from compact, cheap hardware. Their handheld device — about the size of a cigarette pack — uses laser illumination and 8-camera-chip arrays to image blood flow at 20x the resolution of multi-million-dollar MRI machines, at a fraction of the cost. The technology is already deployed in hospitals over the past four years and entering production.

The therapeutic applications are equally striking. Using focused ultrasound at diagnostic (safe) power levels through an 8x8 transducer array and antenna theory beam-steering, Open Water is clearing 80% of amyloid microplaques in lab settings, reducing particle diameter from 8 microns to 4 microns — significant because capillaries are 5-10 microns wide. This has implications for aging, neurodegeneration, acute COVID, and type 2 diabetes. The “opera singer breaking a wine glass” analogy describes how resonant frequencies can selectively attack microclots without harming surrounding tissue. Jepsen also discusses Vitalik Buterin’s $50M offer to open-source Open Water’s 68 patents, software, and hardware under AGPL — a move that could unleash a broader research community.

Career backstory includes building the world’s first computer-generated hologram with micron-size pixels (1987), designing the OLPC laptop around the screen (not the CPU) with BYD lithium iron phosphate batteries achieving 2,000 charge cycles, and her philosophy that “impossible” means “impossible for them.”

Bias/Sponsor Notes

Standard Diamandis ad reads for Viome (portfolio company) and Longevity Guidebook (his own book). The interview is genuinely substantive — Jepsen is a credible technical founder with real results in hospitals. However, Diamandis’s framing is extremely optimistic (“Nobel Prize,” “most important revolution in healthcare”) without clinical trial data discussion, FDA pathway, or skeptical questioning of the lab-to-clinic gap. Open Water’s open-source pivot via Buterin funding is presented uncritically as purely positive.